Abbott Laboratories Will Outperform Healthcare Stocks in 2025
The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson (NYSE: JNJ) higher in 2025. While each produced a solid quarter, Abbott Laboratories outperformed and has a more robust outlook.
Why Is Abbott Laboratories (ABT) Stock Surpassing 6.96% from Its 50-Day SMA?
Oppenheimer has recently initiated Abbott Laboratories (ABT) stock to Outperform rating, as announced on October 8, 2024, according to Finviz. Earlier, on September 19, 2024, Piper Sandler had initiated the stock to Overweight,
Abbott Laboratories (ABT) Q4 2024 Earnings Call Transcript
Abbott Laboratories (NYSE: ABT) Q4 2024 Earnings Call Jan 22, 2025, 9:30 a.m. ET
Abbott Laboratories (NYSE:ABT) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript January 22, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is $1.34 EPS, expectations were $1.34. Operator: Good morning and thank you for standing by.
Why Abbott Laboratories (ABT) Stock is Currently 2.73% Above from Its 20-Day SMA?
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.66% of Abbott Laboratories (ABT)’s shares, while financial institutions hold 76.57%.
Abbott Laboratories stock outperforms competitors on strong trading day
Shares of Abbott Laboratories rose 4.62% to $123.22 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.53% to 6,118.71 and the Dow Jones Industrial Average rising 0.
Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings.
Abbott Laboratories posts total worldwide sales of $10.97 billion for the quarter ended Dec. 31, missing Wall Street estimates of $11.03 billion.
Abbott Laboratories' SWOT analysis: stock poised for growth amid challenges
Abbott Laboratories (NYSE: NYSE:ABT) has demonstrated resilience and growth potential in the healthcare sector, maintaining a strong financial profile despite facing various challenges. According to InvestingPro data,
Abbott Labs' Ensure, made in Columbus, hits multibillion-dollar milestone
A product made in Columbus reached a major milestone at the end of 2024. Ensure, a nutritional drink made by Abbott ...
Abbott Q4 Earnings Meet, Margins Down, Stock Falls in Pre-Market
Abbott Laboratories ABT reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.34, in line with the Zacks ...
RBC Capital Sticks to Its Buy Rating for Abbott Laboratories (ABT)
In a report released yesterday, Shagun Singh Chadha from RBC Capital reiterated a Buy rating on Abbott Laboratories (ABT – Research Report), ...
Abbott Labs Q4 Earnings And Q1 Profit Guidance Lags Street View, Worldwide COVID-19 Testing Sales Fall
Abbott's Q4 sales reached $10.97 billion, with 8.8% organic growth. EPS met expectations at $1.34, driven by strong ...
Jim Cramer on Abbott Laboratories (ABT): ‘I Think Abbott Will Win These Baby Formula Cases’
We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where ...
Wells Fargo Sticks to Their Buy Rating for Abbott Laboratories (ABT)
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of ...